Midol IB and Rosiglitazone Maleate

• Generic Name: ibuprofen
• Dosage Forms: n.a.
• Other Brand Names: Advil, Genpril, Ibu, Midol IB, Motrin IB, Proprinal, Smart Sense Children's Ibuprofen, Advil Liqui-Gels, Midol, Motrin, Motrin Migraine Pain, PediaCare Children’s Pain Reliever/Fever Reducer, PediaCare Infant’s Pain Reliever/Fever Reducer, Caldolor, NeoProfen, Children's Motrin, Motrin Junior Strength

Midol IB is a nonsteroidal anti-inflammatory drug (NSAID). This medicine works by reducing hormones that cause inflammation and pain in the body.

Midol IB is used to reduce fever and treat pain or inflammation caused by many conditions such as headache, toothache, back pain, arthritis, menstrual cramps, or minor injury. Midol IB is used in adults and children who are at least 6 months old.

Midol IB may also be used for purposes not listed in this medication guide.

• Generic Name: rosiglitazone
• Dosage Forms: n.a.
• Other Brand Names: Avandia

Used as monotherapy or in combination with a sulfonylurea, metformin, or a sulfonylurea and metformin as an adjunct to diet and exercise for the management of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM).

May be added to glyburide/metformin fixed-combination therapy if hyperglycemia is not adequately controlled with the fixed combination.

May be used in combination with repaglinide if hyperglycemia is not adequately controlled with repaglinide monotherapy.

May use fixed combination of rosiglitazone/metformin (Avandamet) when treatment with rosiglitazone and metformin is appropriate.

May use fixed combination of rosiglitazone/glimepiride (Avandaryl) when treatment with rosiglitazone and glimepiride is appropriate.

Metformin is the preferred initial oral antidiabetic agent for patients with type 2 diabetes mellitus. Thiazolidinediones are one of several second-line agents used with other oral antidiabetic agents (e.g., metformin) in patients who are inadequately controlled on their current oral therapy. Because of potential for serious adverse effects, American Diabetes Association (ADA) recommends that clinicians carefully weigh the potential risks and benefits of thiazolidinediones versus other second-line agents (i.e., insulin, sulfonylureas).

Use in combination with insulin not recommended.

Because endogenous insulin is required for activity, not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.